Compositions and methods for enhancing the viability of animal cells, tissues, and organ explants

Patent metadata

Field	Value
Publication number	US-9737071-B2
Application number	US-201414582837-A
Country	US
Kind code	B2
Filing date	Dec 24, 2014
Priority date	Jul 12, 2007
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

Disclosed are compositions and methods for the preservation, storage, and transport of living biological tissues, organs, and populations of isolated cells. In particular, the disclosed compositions and processes permit mammalian cells, tissues, and organs to be harvested from suitable donor animals, stored for prolonged periods, and transported to the site of recipient implantation, all without significant loss of cell viability, biological activity, and/or tissue integrity.

First claim

What is claimed is:

1. A composition comprising:
a) a biological buffer, medium, tissue storage buffer or organ transport solution;
b) a first polyethylene glycol and a second polyethylene glycol, the second polyethylene glycol having a different average molecular weight from the first polyethylene glycol;
c) at least a first chelator selected from the group consisting of deferoxamine mesylate, 2,2′-dipyridyl, and 1,10-phenanthroline; and
d) at least a first antioxidant selected from the group consisting of ascorbic acid and 2,6-di-tert-butyl-4-methylphenol;

wherein each of b), c), and d) is present in said composition in an amount effective to prolong the viability of a biological sample maintained in said composition compared to maintenance of said biological sample stored in said biological buffer, medium, tissue storage buffer, or organ transport solution alone.

2. The composition of claim 1 , wherein:
a) the first polyethylene glycol is present in said composition at a concentration of between about 0.01% (vol./vol.) and about 30% (vol./vol);
b) said at least a first chelator is present in said composition at a concentration of between about 0.01 μM and about 100 μM; or
c) said at least a first antioxidant is present in said composition at a concentration of between about 0.0001% (vol./vol.) and about 0.30% (vol./vol.).

3. The composition of claim 1 , further comprising at least a second distinct antioxidant, wherein said at least a first antioxidant is ascorbic acid, and
said at least a second distinct antioxidant is 2,6-di-tert-butyl-4-methylphenol.

4. A method for storing a biological sample, comprising:
a) contacting a biological sample with a composition according to claim 1 :

and
b) maintaining said sample in said composition at a temperature of from between about −10° C. and about 25° C.,

wherein said biological sample remains substantially viable after maintaining said sample in said composition for a period of at least about 14 days.

5. The method of claim 4 , wherein said biological sample comprises a population of mammalian cells, a mammalian tissue, a mammalian organ, a tissue engineered construct or a tissue engineered device.

6. The method of claim 5 , wherein at least about 70% of said biological sample remains substantially viable after maintaining said sample in said composition for a period of at least about 21 days.

7. The method of claim 6 , wherein at least about 70% of said biological sample remains substantially viable after maintaining said sample in said composition for a period of at least about 42 days.

8. The method of claim 7 , wherein at least about 50% of said biological sample remains substantially viable after maintaining said sample in said composition for a period of at least about 58 days.

9. The method of claim 4 , wherein the first polyethylene glycol is present in said composition at a concentration of between about 0.10% (vol./vol.) and about 10% (vol./vol.).

10. The method of claim 4 , wherein said mixture comprises at least a first polyethylene glycol having an average molecular weight of about 600 Da, and at least a second polyethylene glycol having an average molecular weight of about 3350 Da.

11. The method of claim 10 , wherein each of said first and said second polyethylene glycols is present in said composition at a concentration of from between about 0.1% and 5% (vol./vol.).

12. The method of claim 11 , wherein each of said first and said second polyethylene glycols is present in said composition at a concentration of about 1.3%.

13. The method of claim 4 , wherein said at least a first chelator is present in said composition at a concentration of between about 0.01 μM and about 20 μM.

14. The method of claim 4 , wherein said compound is deferoxamine mesylate.

15. The method of claim 4 , wherein said at least a first antioxidant is present in said composition at a concentration of between about 0.010% (vol./vol.) and about 1.0% (vol./vol.).

Assignees

• Warsaw Orthopedic Inc

Inventors

• Shimko Daniel Andrew
• Noel Scott P
• Drapeau Susan J
• Roy Josee

Classifications

• A01N1/0226 Primary

  Human Necessities · mapped topic

• A01N1/02

  Human Necessities · mapped topic

• C12N5/0018

  Culture media for cell or tissue culture (media for specific animal cell type C12N5/06) · CPC title

• C12N2500/30

  Organic components · CPC title

• A01N1/021

  Human Necessities · mapped topic